Nuvation Bio Inc. (NYSE:NUVB - Get Free Report)'s share price gapped up prior to trading on Wednesday . The stock had previously closed at $2.05, but opened at $2.14. Nuvation Bio shares last traded at $2.23, with a volume of 2,024,606 shares.
Wall Street Analysts Forecast Growth
NUVB has been the topic of a number of analyst reports. Royal Bank Of Canada raised Nuvation Bio from an "outperform" rating to a "moderate buy" rating and dropped their price target for the stock from $10.00 to $6.00 in a research note on Tuesday, June 17th. JMP Securities reissued a "market outperform" rating and issued a $6.00 price target on shares of Nuvation Bio in a research report on Wednesday, June 25th. Wall Street Zen downgraded shares of Nuvation Bio from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. Jones Trading initiated coverage on Nuvation Bio in a report on Wednesday, March 12th. They set a "buy" rating and a $10.00 price objective on the stock. Finally, Wedbush reaffirmed an "outperform" rating and set a $5.00 price objective on shares of Nuvation Bio in a report on Wednesday, June 11th. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $7.17.
Get Our Latest Report on Nuvation Bio
Nuvation Bio Trading Down 2.3%
The firm has a market cap of $787.71 million, a price-to-earnings ratio of -0.99 and a beta of 1.33. The stock's 50 day moving average is $2.14 and its 200 day moving average is $2.20.
Nuvation Bio (NYSE:NUVB - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.16) EPS for the quarter, meeting the consensus estimate of ($0.16). The business had revenue of $3.08 million during the quarter, compared to the consensus estimate of $0.42 million. Nuvation Bio had a negative net margin of 5,534.21% and a negative return on equity of 44.14%. On average, equities research analysts predict that Nuvation Bio Inc. will post -0.36 EPS for the current year.
Insider Buying and Selling
In other Nuvation Bio news, insider Dongfang Liu sold 20,000 shares of the firm's stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $2.50, for a total value of $50,000.00. Following the transaction, the insider directly owned 12,000 shares of the company's stock, valued at approximately $30,000. This trade represents a 62.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 29.93% of the company's stock.
Institutional Trading of Nuvation Bio
Several hedge funds have recently added to or reduced their stakes in NUVB. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Nuvation Bio in the fourth quarter worth about $27,000. Forum Financial Management LP purchased a new position in Nuvation Bio in the 4th quarter worth approximately $29,000. Cerity Partners LLC purchased a new position in Nuvation Bio in the 4th quarter worth approximately $31,000. Russell Investments Group Ltd. grew its stake in Nuvation Bio by 15,183.7% in the 4th quarter. Russell Investments Group Ltd. now owns 15,895 shares of the company's stock worth $42,000 after buying an additional 15,791 shares in the last quarter. Finally, Cibc World Markets Corp bought a new stake in shares of Nuvation Bio in the 4th quarter worth approximately $45,000. Institutional investors own 61.67% of the company's stock.
Nuvation Bio Company Profile
(
Get Free Report)
Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.
Read More
Before you consider Nuvation Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvation Bio wasn't on the list.
While Nuvation Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.